<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02887625</url>
  </required_header>
  <id_info>
    <org_study_id>NPRP 5-273-3-079</org_study_id>
    <nct_id>NCT02887625</nct_id>
  </id_info>
  <brief_title>Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM</brief_title>
  <official_title>Efficacy and Durability of Glucagon Like Peptide 1 Receptor Agonists (GLP-1 RA)/Thiazolidinedione Versus Basal Bolus Insulin Therapy in Poorly Controlled Type 2 Diabetic Patients (T2DM) Patients on Sulfonylurea Plus Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Muhammad Abdulghani</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare efficacy, safety and durability of combination therapy with pioglitazone plus
      GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus
      sulfonylurea
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      poorly controlled (HbA1c &gt;7.5%) T2DM patients (18-75 years of age) on maximal/near maximal
      dose of sulfonylurea plus metformin who otherwise are healthy will be randomized to receive:

        1. exenatide weekly injection (2 mg/week)

        2. glargine insulin plus insulin aspart which will be titrated to maintain HbA1c &lt;7.0%
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>3 years</time_frame>
    <description>difference in HbA1c between the two treatment groups will be compared at 1 and at 3 years to determine efficacy and durability of each treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of patients who achieve HbA1c &lt;7.0% and &lt;6.5% at 1 year and at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypoglycemia rate</measure>
    <time_frame>3 years</time_frame>
    <description>will be measured as absolute event rate per patient year of follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the FPG</measure>
    <time_frame>3 years</time_frame>
    <description>change in FPG from time zero to 1 year and from baseline to 3 years in each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in body weight</measure>
    <time_frame>3 years</time_frame>
    <description>change in body weight from time zero to 1 year and to 3 years in each treatment group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">410</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pioglitazone (actos) 30 mg per day and exenatide (bydureon) 2 mg per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>insulin glargine (lantus) will be started every morning and the dose will be weekly increase to achieve fasting plasma glucose (FPG) &lt;110 mg/dl.
and Aspart insulin will be started before meals and the dose is adjusted to maintain HbA1c &lt;7.0% and postprandial plasma glucose (PPG) &lt;140 mg/dl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone plus exenatide</intervention_name>
    <description>pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>actos and bydureon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine and insulin aspart</intervention_name>
    <description>the dose will be escalated to maintain HbA1c &lt;7.0%</description>
    <arm_group_label>Insulin Therapy</arm_group_label>
    <other_name>lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2DM poorly controlled (HbA1c &gt;7.5%) on metformin (&gt;1700 mg/day) plus sulfonylurea

        Exclusion Criteria:

          -  type 1 diabetes (T1DM) patients receiving therapy with pioglitazone, GLP-1 RA and
             insulin abnormal kidney, liver or heart function patients with malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amin Jayyousi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Abdul-Ghani, MD, PhD</last_name>
    <phone>44391208</phone>
    <email>ABDULGHANI@UTHSCSA.EDU</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amin Jayyousi, MD</last_name>
    <phone>55530236</phone>
    <email>ajayyousi@hamad.qa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamad General Hospital</name>
      <address>
        <city>Doha</city>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osama Mujahed, MD</last_name>
      <phone>66703172</phone>
      <email>pvedromigahid@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ayman Mujahed, MD</last_name>
      <phone>44391208</phone>
      <email>ymndodo20@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hamad Medical Corporation</investigator_affiliation>
    <investigator_full_name>Dr. Muhammad Abdulghani</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

